Atossa Therapeutics, Inc. to Present Poster on (Z)-Endoxifen at #AACR Special Conference in Cancer Research #breastcancer #research #innovation $ATOS https://lnkd.in/epQ9BUV4
Atossa Therapeutics, Inc.’s Post
More Relevant Posts
-
Advanced Therapies Certified | Visiting Assistant Research Professor | Trusted Consultant
🎉Congratulations to Indapta Therapeutics! Check out these abstracts at the Society for Immunotherapy of Cancer (SITC) meeting. #cellulartherapy #allogeneic #NKcells
Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting
businesswire.com
-
#STEAP1, a protein often overexpressed in prostate cancer, is becoming a key focus in cancer research. Understanding STEAP1's role in cancer can lead to better diagnostic tools and targeted therapies, potentially improving outcomes for patients. As research continues, STEAP1 might become a crucial component in the fight against cancer. https://lnkd.in/ehz_EPts 🧬 #CancerResearch #STEAP1 #ProstateCancer #Biomarkers #MedicalResearch
STEAP1 – A Therapeutic Target for Prostate Cancer
https://www.dimabio.com
-
Consultant: preclinical management and business strategy for Biotechs in Neuroscience and Oncology
I am delighted to share the announcement of a #collaboration that I have initiated and will be leading on behalf of my client OregonTherapeutics trough my service Lab2BIOTECH. This collaboration involves the analysis of the #preclinical package of Oregon Therapeutics' lead product, XCE853, by Lantern Pharma Inc. (Nasdaq: LTRN) Pharma's #AI based RADR® platform, in order to identify the best clinical positioning of this #drug candidate for #Cancer patient's and further progress toward clinics together. Please see the press release below. --- Personal notes: This is AI as I like it: no buzzwords, concrete analysis of huge datasets and literature points to leverage smarter strategies in #drugdevelopment and improve patient's impact. This collaboration is also a good illustration of my vision on how best to develop assets for startups. Licensing a drug candidate is not a final step at the end of a development plan. It's an ongoing process, starting from day one of project management, and requires open-mindedness, seeking out opportunities and collaborating with potential licensees to build trust and improve product-market fit with payers' expectations, while driving R&D forward. Tip for founders: surround yourself!
Healthcare, Life Sciences & Biotech Entrepreneur & Executive | Bringing together AI and Drug Development
This morning we announced another #AI powered #collaboration where our platform for cancer #drugdevelopment will be used to sharpen and accelerate the first-in-class work being done by OregonTherapeutics in France in the area of PDI (protein disulfide isomerase) inhibitors which have a high potency impact on #cancer metabolism. We look forward to more collaborations where we can leverage our oncology focused #AI platform to help transform the pace and risk of developing #newmedicines for cancer patients.
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
businesswire.com
-
The future of cancer treatment relies on the advancement of mAbs, bsAbs, ADCs, and biosimilar research. Our latest eBook explores the pivotal role of high-throughput instruments in accelerating next-gen therapies. #CancerResearch #Oncology
The Path from Traditional Monoclonal Antibodies to Next- Generation Constructs | Ebooks
labroots.com
-
The future of cancer treatment relies on the advancement of mAbs, bsAbs, ADCs, and biosimilar research. Our latest eBook explores the pivotal role of high-throughput instruments in accelerating next-gen therapies. #CancerResearch #Oncology
The Path from Traditional Monoclonal Antibodies to Next- Generation Constructs | Ebooks
labroots.com
-
⭐️KACTUS's GMP-grade base editing enzyme has played a pivotal role in contributing to the IND filling of a NK cell injection cancer therapy⭐️ Utilizing KACTUS's base editing enzyme, AccuBase™, in their NK510 cell injection Base Therapeutics moves one step closer to IND approval. This marks a significant milestone in cancer therapy, and showcases the immersive potential of GMP-grade base editors in CGT manufacturing. 🔗 Discover the full story: https://bit.ly/3WJuF8n
AccuBase™: The Cutting-Edge Base Editing Enzyme Driving Breakthroughs of NK Cell Cancer Therapy
kactusbio.com
-
The future of cancer treatment relies on the advancement of mAbs, bsAbs, ADCs, and biosimilar research. Our latest eBook explores the pivotal role of high-throughput instruments in accelerating next-gen therapies. #CancerResearch #Oncology
The Path from Traditional Monoclonal Antibodies to Next- Generation Constructs | Ebooks
labroots.com
-
Inspirational Business Keynote & Author Speaker | Founder & CEO at BluChip Solutions | Board of Directors at Coeptis Therapeutics | NSA Member
Copeptis is at the Forefront of Innovation: How Coeptis is Shaping the Future of Cell Therapy for Cancer Treatment
Coeptis’ cutting-edge #celltherapy platforms are making research strides in the fight against cancer and other debilitating diseases. Explore how we are innovating #celltherapy approaches and developments here: https://bit.ly/3ThpQ4q #Oncology #OncNews #Biotech #Biopharma #CancerResearch
Here's How Coeptis Therapeutics Is Innovating Cell Therapy Approaches - Actinium Pharma (AMEX:ATNM), Bristol-Myers Squibb (NYSE:BMY)
benzinga.com
-
𝗜𝗡𝟴𝗕𝗶𝗼 𝗗𝗼𝘀𝗲𝘀 𝗙𝗶𝗿𝘀𝘁 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗼𝗳 𝗜𝗡𝗕-𝟰𝟬𝟬 𝗶𝗻 𝗡𝗲𝘄𝗹𝘆 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗲𝗱 𝗚𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 Congrats to the entire team at IN8bio who've just announced that the first patient in their Phase 2 trial for INB-400, an innovative gamma-delta T cell therapy, has been successfully dosed at the Cleveland Clinic in Ohio. This trial is a major step forward in the fight against glioblastoma multiforme, a highly aggressive brain cancer. INB-400 combines the power of gamma-delta T cells with standard treatments like temozolomide to offer new hope for GBM patients. #GammaDeltaTCells #CGT #In8Bio
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
finance.yahoo.com
-
Investigational THIO: Our preclinical findings show that THIO works against difficult-to-treat tumor types that are generally unresponsive to CPI immunotherapy alone. Dive into the highlights here: https://bit.ly/3Tk7f7M #Immunotherapy #Oncology
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
ir.maiabiotech.com
